Orano Med has broken ground on a $265 million thorium production site, named the Advanced Thorium Extraction Facility, designed to supply alpha therapy labs worldwide with lead-212 for cancer treatments. The facility, spanning 7,000 square meters, is slated to open in 2027.
Addressing the Need for Lead-212
Treatments developed by Orano Med require a stable supply of lead-212. The new facility aims to meet this demand and support the broader development of radioligand therapies. According to Arnaud Lesegretain, CEO of Orano Med, radioligand therapies are poised to become essential in cancer treatment. "We are convinced that radioligand therapies will soon become an essential tool in the fight against cancer," Lesegretain stated.
AlphaMedix: A Phase II Asset
Orano Med has its own drug in development, AlphaMedix, which is currently in Phase II clinical trials as a cancer treatment. AlphaMedix utilizes lead-212 in its therapeutic approach. As the Phase II clinical trial of AlphaMedix nears completion, Orano Med is investing in infrastructure to support the large-scale production and distribution of lead-212-based treatments.
Integrated Industrial Platform
The Advanced Thorium Extraction Facility represents a globally unique integrated industrial platform, according to Orano Med. This platform is designed to ensure the reliable and scalable production of lead-212, a critical component in the company's pipeline of radioligand therapies.
